MeSH tree: D13.570.800.286
Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to ...
5 hours ago
0
0
For years, treatment of older patients with acute myeloid leukemia—an aggressive cancer of the blood and bone marrow—has required injections administered in a clinic for five to seven consecutive days each month, in addition ...
Jun 10, 2026
0
6
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form ...
Jun 4, 2026
0
4
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
Dec 29, 2025
0
97
Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The findings suggest that ...
Aug 6, 2025
0
11
Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic leukemia (CMML), a rare and aggressive form of blood cancer.
Jul 31, 2025
0
24
Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment—immunotherapy—may help change the environment where cancer cells live, possibly helping the ...
Jul 29, 2025
0
20
The targeted drug olutasidenib is highly effective in certain patients with myelodysplastic syndrome (MDS), a condition considered incurable without transplantation, according to a new clinical study led by researchers at ...
Jul 28, 2025
0
21
Even treated with the most advanced therapies, patients with glioblastoma—an aggressive brain cancer—typically survive less than two years after diagnosis. Efforts to treat this cancer with the latest immunotherapies have ...
Nov 7, 2024
0
36
A team from the Wistar Institute has demonstrated the role of Parkin—a protein implicated in Parkinson's disease—in the body's innate immune response to cancer. Parkin is not expressed in several cancers.
Sep 18, 2024
0
45
